A Phase 3 interventional study of Lucerastat and Placebo in Fabry Disease, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one has the largest enrollment, is one of 3 that started in 2018, is one of 11 in phase 3, and was the 14th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2018.
This study's enrollment of 118 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Idorsia Pharmaceuticals Ltd. has 5 studies filed under Fabry Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.
The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Enzyme replacement therapy (ERT) status:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lucerastat
Drug: Placebo
Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Neuropathic Pain Monthly Score: Change From Baseline to Month 6
Neuropathic pain on the modified BPI-SF3: subjects rated their neuropathic pain intensity ("neuropathic pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no neuropathic pain) to 10 (worst imaginable neuropathic pain).
Time frame: From baseline to Month 6 (duration: 6 months)
Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6
Time frame: From baseline to Month 6 (duration: 6 months)
Abdominal Pain Monthly Score: Change From Baseline to Month 6
Abdominal pain on the 11-point Numerical Rating Scale (NRS-11): subjects rated their abdominal pain intensity ("abdominal pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no pain) to 10 (worst imaginable pain).
Time frame: From baseline to Month 6 (duration: 6 months)
Number of Days With Diarrhea: Change From Baseline to Month 6
A subject was considered to have diarrhea on a specific day if at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 was reported. The number of days with diarrhea at baseline and Month 6 was the number of days with diarrhea over the 4 weeks prior to the randomization visit or the Month 6 visit, respectively, adjusted for the number of days with data available.
Time frame: From baseline to Month 6 (duration: 6 months)
The study was conducted at 49 sites in 14 countries, including North America (USA, CAN), Europe (Austria, Belgium, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Switzerland, UK), and Australia.
| Milestone | Lucerastat | Placebo |
|---|---|---|
| Started | 80 | 38 |
| Treated | 80 | 37 |
| Completed | 75 | 34 |
| Not completed | 5 | 4 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Neuropathic pain on the modified BPI-SF3: subjects rated their neuropathic pain intensity ("neuropathic pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no neuropathic pain) to 10 (worst imaginable neuropathic pain).
| score on a scale | Lucerastat | Placebo |
|---|---|---|
| Neuropathic Pain Monthly Score: Change From Baseline to Month 6 | -1.64 (-2.11 to -1.16) | -2.05 (-2.73 to -1.37) |
| ng/ml | Lucerastat | Placebo |
|---|---|---|
| Plasma Globotriaosylceramide (Gb3; in ng/ml): Change From Baseline to Month 6 | -672.68 (-798.91 to -546.46) | 200.84 (14.29 to 387.40) |
Abdominal pain on the 11-point Numerical Rating Scale (NRS-11): subjects rated their abdominal pain intensity ("abdominal pain at its worst in the last 24 hours") on an 11-point scale, from 0 (no pain) to 10 (worst imaginable pain).
| score on a scale | Lucerastat | Placebo |
|---|---|---|
| Abdominal Pain Monthly Score: Change From Baseline to Month 6 | -1.37 (-1.86 to -0.87) | -1.68 (-2.38 to -0.98) |
A subject was considered to have diarrhea on a specific day if at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 was reported. The number of days with diarrhea at baseline and Month 6 was the number of days with diarrhea over the 4 weeks prior to the randomization visit or the Month 6 visit, respectively, adjusted for the number of days with data available.
| Number of days within 4 weeks | Lucerastat | Placebo |
|---|---|---|
| Number of Days With Diarrhea: Change From Baseline to Month 6 | -3.45 ± 4.96 | -3.95 ± 9.29 |
Collected over Treatment-emergent adverse events from the 6-month treatment period are reported. Adverse events were considered treatment-emergent if the onset date was between the first intake of study treatment up to 30 days after the end of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lucerastat | 0/80 (0%) | 5/80 (6.3%) | 46/80 (57.5%) |
| Placebo | 0/37 (0%) | 1/37 (2.7%) | 21/37 (56.8%) |
| Event | Lucerastat | Placebo |
|---|---|---|
| Tooth abscessInfections and infestations | 0/80 | 1/37 |
| Ventricular tachycardiaCardiac disorders | 1/80 | 0/37 |
| Vertigo positionalEar and labyrinth disorders | 1/80 | 0/37 |
| Drug withdrawal syndromeGeneral disorders | 1/80 | 0/37 |
| Hepatitis viralInfections and infestations | 1/80 | 0/37 |
| Localised infectionInfections and infestations | 1/80 | 0/37 |
| Septic encephalopathyInfections and infestations | 1/80 | 0/37 |
| Streptococcal bacteraemiaInfections and infestations | 1/80 | 0/37 |
| Ischaemic strokeNervous system disorders | 1/80 | 0/37 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/80 | 0/37 |
| Event | Lucerastat | Placebo |
|---|---|---|
| FatigueGeneral disorders | 3/80 | 6/37 |
| NauseaGastrointestinal disorders | 11/80 | 1/37 |
| NasopharyngitisInfections and infestations | 8/80 | 5/37 |
| DiarrhoeaGastrointestinal disorders | 9/80 | 1/37 |
| HeadacheNervous system disorders | 9/80 | 4/37 |
| Abdominal distensionGastrointestinal disorders | 4/80 | 4/37 |
| Glomerular filtration rate decreasedInvestigations | 0/80 | 4/37 |
| FlatulenceGastrointestinal disorders | 7/80 | 1/37 |
| NeuralgiaNervous system disorders | 6/80 | 3/37 |
| VomitingGastrointestinal disorders | 6/80 | 0/37 |
| Age, Continuous(years) | Lucerastat | Placebo | Total |
|---|---|---|---|
| Median | 38 (18 to 74) | 39 (18 to 65) | 39 (18 to 74) |
| Sex: Female, Male(Participants) | Lucerastat | Placebo | Total |
|---|---|---|---|
| Female | 43 | 20 | 63 |
| Male | 37 | 18 | 55 |
| Race (NIH/OMB)(Participants) | Lucerastat | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 76 | 37 | 113 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | Lucerastat | Placebo | Total |
|---|---|---|---|
| United States | 26 | 6 | 32 |
| United Kingdom | 8 | 3 | 11 |
| Switzerland | 0 | 1 | 1 |
| Spain | 7 | 6 | 13 |
| Canada | 10 | 5 | 15 |
| Netherlands | 1 | 2 | 3 |
| Austria | 0 | 1 | 1 |
| Belgium | 3 | 1 | 4 |
| Norway | 1 | 1 | 2 |
| Poland | 9 | 4 | 13 |
| Australia | 5 | 4 | 9 |
| Germany | 10 | 4 | 14 |
| Neuropathic pain monthly score at baseline(units on a scale) | Lucerastat | Placebo | Total |
|---|---|---|---|
| Mean | 6.26 ± 1.54 | 6.11 ± 1.39 | 6.21 ± 1.49 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Aug 2021, 37 months.
Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in Aug 2022.
Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat
Idorsia Pharmaceuticals Ltd. →